Syndax Pharmaceuticals Inc(SNDX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:01 PM ET (Korea 10/27 05:01)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.52 | Insider Own | 9.12% | Shs Outstand | 89.2M | Perf Week | 0.88% |
| Market Cap | 1.18B | Forward P/E | - | EPS next Y | 59.55% | Insider Trans | -1.28% | Shs Float | 81.2M | Perf Month | -27.45% |
| Enterprise Value | 1.22B | PEG | - | EPS next Q | -0.49 | Inst Own | 115.36% | Short Float | 22.47% | Perf Quarter | -32.73% |
| Income | -0.22B | P/S | 4.67 | EPS this Y | 38.69% | Inst Trans | 10.34% | Short Ratio | 10.04 | Perf Half Y | -37.12% |
| Sales | 0.25B | P/B | 77.97 | EPS next 5Y | - | ROA | -33.97% | Short Interest | 18.23M | Perf YTD | -37.15% |
| Book/sh | 0.17 | P/C | 2.15 | EPS past 3/5Y | -10.26% -12.05% | ROE | -255.93% | 52W High | -48.4% ($25.59) | Perf Year | -2.4% |
| Cash/sh | 6.14 | P/FCF | - | Sales past 3/5Y | - 157.68% | ROIC | -36.55% | 52W Low | 3.2% ($12.80) | Perf 3Y | 4.22% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 35.43% | Gross Margin | 95.77% | Volatility(W/M) | 3.73% 4.56% | Perf 5Y | -30.86% |
| Dividend TTM | - | EV/Sales | 4.84 | Sales Y/Y TTM | 222.65% | Oper. Margin | -76.98% | ATR (14) | 0.76 | Perf 10Y | 2.84% |
| Dividend Ex-Date | - | Quick Ratio | 6.44 | EPS Q/Q | 33.35% | Profit Margin | -87.52% | RSI (14) | 27.21 | Recom | 1.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.77 | Sales Q/Q | 91.76% | SMA20 | -14.59% ($15.45) | Beta | 0.47 | Target Price | $37.27 |
| Payout | - | Debt/Eq | 39.03 | Earnings | 2026/8/4 | SMA50 | -25.27% ($17.66) | Rel Volume | 1.1 | Prev Close | $13.4 |
| Employees | 298 | LT Debt/Eq | 39 | EPS/Sales Surpr. | -22.85% -8.29% | SMA200 | -35.19% ($20.37) | Avg Volume(3M) | 1.82M | Price | $13.2 |
| IPO | 2016/3/3 | Option/Short | Yes/Yes | Trades | 11274 | Volume | 1,990,849 | Change | -1.46% |
🧬 This is a U.S. biotech company that develops and commercializes therapeutics for cancer and immune-related diseases. It has commercialized treatments targeting blood cancers such as leukemia, as well as immune conditions related to transplantation, and is developing pipeline candidates with differentiated mechanisms of action. Combining its commercial products with its oncology and immunology pipeline, the company is a biotech building a foothold in underserved disease markets.
Over the past 1 year, on the lower side
48% below its 1-year high.
Traded about as much as usual. That is 110% of its average volume.
SNDX has a sound balance sheet but weak earning power
Of every $100 in sales, $76.98 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +38.7% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $467. Peers typically go for $1,091.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -30.9%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
22.5% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #145 of 594 in the industry
Based on market cap of $1B.
DRTS#142 Alpha Tau Medical Ltd $1B PER - 
KARD#143 Kardigan Inc $1B PER - 
OMER#144 Omeros Corp $1B PER 11.3 SNDX#145 Syndax Pharmaceuticals Inc $1B PER - 
REPL#146 Replimune Group Inc $1B PER - 
FAQ
What kind of company is SNDX?
SNDX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SNDX?
The market cap of SNDX is approximately $1.2B, ranking 2,438 within its sector.
What is the 52-week high and low for SNDX?
SNDX has recorded a 52-week high of $25.59 and a low of $12.80.
